| Altername | AXIL; ODCRCS |
| Swiss-Prot No. | Q9Y2T1 |
| Specificity | IgG |
| Recommended Dilutions | WB: 1:1000 | IHC: 1:20 | ICC/IF: 1:20 |
| Purification | Affinity Purification |
| Molecular Weight | 94 kDa |
| Immunogen | A synthetic peptide of human Axin 2 |
| Conjugate | Unconjugated |
| Modification | Unmodification |
| Storage/Stability | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. |
| Formulation | Store at -20°C. Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt |
Background
The Axin-related protein, Axin2, presumably plays an important role in the regulation of the stability of beta-catenin in the Wnt signaling pathway, like its rodent homologs, mouse conductin/rat axil. In mouse, conductin organizes a multiprotein complex of APC (adenomatous polyposis of the colon), beta-catenin, glycogen synthase kinase 3-beta, and conductin, which leads to the degradation of beta-catenin. Apparently, the deregulation of beta-catenin is an important event in the genesis of a number of malignancies. The AXIN2 gene has been mapped to 17q23-q24, a region that shows frequent loss of heterozygosity in breast cancer, neuroblastoma, and other tumors. Mutations in this gene have been associated with colorectal cancer with defective mismatch repair.